Skip to main content
. 2019 Jan 10;14:550–561. doi: 10.1016/j.omtn.2019.01.001

Figure 2.

Figure 2

Combination of ERK Inhibitor and Everolimus Synergistically Reduces the Viability of RCC Cells

(A) Caki-1 and 786-O cells were treated with everolimus alone or in combination with ERK inhibitor SCH772984 for 72 h. The cell viability was assessed by CCK-8 assay. ***p < 0.001. (B) Synergistic effect of everolimus and SCH772984 in Caki-1 and 786-O cells was analyzed using isobologram. The horizontal line indicates the fractional effect of the combination. CI values <1 indicate synergism whereas >1 indicate antagonism. (C) Caki-1 and 786-O cells were treated with everolimus alone or in combination with ERK inhibitor BVD-523 for 72 h. The cell viability was assessed by CCK-8 assay. **p < 0.01; ***p < 0.001. (D) Synergistic effect of everolimus and BVD-523 in Caki-1 and 786-O cells was analyzed using isobologram. The horizontal line indicates the fractional effect of the combination. CI values <1 indicate synergism whereas >1 indicate antagonism. Error bars represent mean ± SD of three independent experiments.